Journal Publications

2020


2019


2018


2017


- Morgen EK, Lenz HJ, Jonker DJ, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis CS,


2016


• Chapman JA, Shepherd LE, Ingle JN, Muss HB, Pritchard KI, Gelmon KA, Whelan TJ, Elliott C, Goss PE. Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast Cancer Res Treat 156:
343-9, 2016.


- Goodwin RA, Jamal R, Booth CM, Goss PE, Eisenhauer EA, Tu D, Shepherd LE.


- Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statist Med n/a, 2016.


• Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac L,


2014


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in


2013


• Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, Davidson NE, Perez EA, Chavarri-Guerra Y, Cameron DA, Pritchard KI, Whelan T, Shepherd LE, Tu D.


- Phipps AI, Shi Q, Newcomb PA, Nelson GD, Sargent DJ, Alberts SR, Limburg PJ.


• Jiang S, Tu D. Inference on the probability as a measurement of treatment effect under a density ratio model and random censoring. Computational Statistics and Data Analysis 56: 1069-78, 2012.


• Liu X, Peng Y, Tu D, Liang H. Variable selection in semiparametric cure models based


- Pritchard K, Munro A, O'Malley FP, Tu D, Li X, Levine M, Shepherd L, Chia S, Bartlett J. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline


**2011**


- Li X, Chen J, Wu Y, Tu D. Constructing Nonparametric Likelihood Confidence Regions

- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis IL, Pritchard KI. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.
- Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zuzewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast...


- Sargent D, Shi Q, Yothers G, Van CE, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de GA. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-6, 2011.

- Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie K,


Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in


- Ocana A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.
**Journal Publications**
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2009


• Au H-J, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H,


DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, on behalf of the American College of Surgeons Oncology Group


2008


- Macdonald DA, Ding K, Gospodorowicz MK, Wells WA, Pearcey RG, Connors JM, Winter JN, Horning SJ, Djurfeldt MS, Shepherd LE, Meyer RM. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with


2006


• Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.

• Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, Eisenhauer E. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the NCIC Clinical


2005


Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan


- Singh S, Parulekar W, Murray N, Feld A, Evans WK, Tu D, Shepherd FA. Influence of


2004


Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP,


2003


- Gridelli C, Gallo C, Shepherd F.A., Illiano A, Piantedosi F, Robbiati S, Manzione L,


2001

• Duivenvoorden WCM, Hirte HW, Singh G. Quantification of matrix metalloproteinase


2000


• Eisenhauer E. Phase I and II evaluation of novel anticancer agents: are response and toxicity the right endpoints? Onkolgie 23(suppl 3): 2-6, 2000.


- Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A,


1999


- Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.

Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1998


• Osoba D, Aaronson N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.


Dent S, Eisenhauer E. Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.


Eisenhauer E. The role of paclitaxel in ovarian cancer treatment. Oncology and Hematology 4: 7-9, 1996.


1995

- Palmer M, McBride J. Working towards a national oncology pharmacists network.


1994


1993


- Pater J, Bacon M. Guest Editorial: Clinical Trials Group of NCIC. Can Onc Nursing J


1990


1989


1987


Sawka CA, Pritchard KI, Paterson AHG, Sutherland DJA, Thomson DB, Shelley WE, Myers RE, Mobbs BG, Malkin A, Meakin JW. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer

1985


1984


1980


1979